Rosa Faner1,2, Tamara Cruz1,2, Teresa Casserras3, Alejandra López-Giraldo1,2, Guillaume Noell2, Ignacio Coca1, Ruth Tal-Singer4, Bruce Miller4, Roberto Rodriguez-Roisin1,2,5, Avrum Spira6, Susana G Kalko3, Alvar Agustí1,2,5. 1. 1 Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain. 2. 2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain. 3. 3 Bioinformatics Platform Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. 4. 4 GSK R&D, King of Prussia, Pennsylvania. 5. 5 Respiratory Institute, Pulmonary Service, Hospital Clinic, Institut d'investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and. 6. 6 Boston University School of Medicine, Boston, Massachusetts.
Abstract
RATIONALE: Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation caused by a combination of airways disease (bronchiolitis) and parenchymal destruction (emphysema), whose relative proportion varies from patient to patient. OBJECTIVES: To explore and contrast the molecular pathogenesis of emphysema and bronchiolitis in COPD. METHODS: We used network analysis of lung transcriptomics (Affymetrix arrays) in 70 former smokers with COPD to compare differential expression and gene coexpression in bronchiolitis and emphysema. MEASUREMENTS AND MAIN RESULTS: We observed that in emphysema (but not in bronchiolitis) (1) up-regulated genes were enriched in ontologies related to B-cell homing and activation; (2) the immune coexpression network had a central core of B cell-related genes; (3) B-cell recruitment and immunoglobulin transcription genes (CXCL13, CCL19, and POU2AF1) correlated with emphysema severity; (4) there were lymphoid follicles (CD20(+)IgM(+)) with active B cells (phosphorylated nuclear factor-κB p65(+)), proliferation markers (Ki-67(+)), and class-switched B cells (IgG(+)); and (5) both TNFRSF17 mRNA and B cell-activating factor protein were up-regulated. These findings were by and large reproduced in a group of patients with incipient emphysema and when patients with emphysema were matched for the severity of airflow limitation of those with bronchiolitis. CONCLUSIONS: Our study identifies enrichment in B cell-related genes in patients with COPD with emphysema that is absent in bronchiolitis. These observations contribute to a better understanding of COPD pathobiology and may open new therapeutic opportunities for patients with COPD.
RATIONALE: Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation caused by a combination of airways disease (bronchiolitis) and parenchymal destruction (emphysema), whose relative proportion varies from patient to patient. OBJECTIVES: To explore and contrast the molecular pathogenesis of emphysema and bronchiolitis in COPD. METHODS: We used network analysis of lung transcriptomics (Affymetrix arrays) in 70 former smokers with COPD to compare differential expression and gene coexpression in bronchiolitis and emphysema. MEASUREMENTS AND MAIN RESULTS: We observed that in emphysema (but not in bronchiolitis) (1) up-regulated genes were enriched in ontologies related to B-cell homing and activation; (2) the immune coexpression network had a central core of B cell-related genes; (3) B-cell recruitment and immunoglobulin transcription genes (CXCL13, CCL19, and POU2AF1) correlated with emphysema severity; (4) there were lymphoid follicles (CD20(+)IgM(+)) with active B cells (phosphorylated nuclear factor-κB p65(+)), proliferation markers (Ki-67(+)), and class-switched B cells (IgG(+)); and (5) both TNFRSF17 mRNA and B cell-activating factor protein were up-regulated. These findings were by and large reproduced in a group of patients with incipient emphysema and when patients with emphysema were matched for the severity of airflow limitation of those with bronchiolitis. CONCLUSIONS: Our study identifies enrichment in B cell-related genes in patients with COPD with emphysema that is absent in bronchiolitis. These observations contribute to a better understanding of COPD pathobiology and may open new therapeutic opportunities for patients with COPD.
Authors: Prescott G Woodruff; Maarten van den Berge; Richard C Boucher; Christopher Brightling; Esteban G Burchard; Stephanie A Christenson; MeiLan K Han; Michael J Holtzman; Monica Kraft; David A Lynch; Fernando D Martinez; Helen K Reddel; Don D Sin; George R Washko; Sally E Wenzel; Antonello Punturieri; Michelle M Freemer; Robert A Wise Journal: Am J Respir Crit Care Med Date: 2017-08-01 Impact factor: 21.405
Authors: Ma'en Obeidat; Yunlong Nie; Nick Fishbane; Xuan Li; Yohan Bossé; Philippe Joubert; David C Nickle; Ke Hao; Dirkje S Postma; Wim Timens; Marc A Sze; Casey P Shannon; Zsuzsanna Hollander; Raymond T Ng; Bruce McManus; Bruce E Miller; Stephen Rennard; Avrum Spira; Tillie-Louise Hackett; Wan Lam; Stephen Lam; Rosa Faner; Alvar Agusti; James C Hogg; Don D Sin; Peter D Paré Journal: Am J Respir Cell Mol Biol Date: 2017-10 Impact factor: 6.914
Authors: Matthew Moll; Adel Boueiz; Auyon J Ghosh; Aabida Saferali; Sool Lee; Zhonghui Xu; Jeong H Yun; Brian D Hobbs; Craig P Hersh; Don D Sin; Ruth Tal-Singer; Edwin K Silverman; Michael H Cho; Peter J Castaldi Journal: Am J Respir Crit Care Med Date: 2022-01-15 Impact factor: 21.405
Authors: Francesca Polverino; Leen J M Seys; Ken R Bracke; Caroline A Owen Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-08-19 Impact factor: 5.464